Genetic alteration of MYC, most commonly gene amplification, was observed in approximately 20% of SCLC, placing it among the most common genetic abnormalities after TP53 and RB1. Higher expression or amplification of MYC predicted sensitivity to CHK1 inhibition in SCLC (19, 59, 60) and Aurora Kinase inhibition (61). The gene discussed is CHEK1; the disease is small cell lung carcinoma.